Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study-Reference-Cited by-同舟云学术

Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study

Published:2018-08-29 Issue:10 Volume:45 Page:1151-1159
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Watanabe Shinichi¹,Tsubouchi Ichiro²,Okubo Akihiro²^ORCID

Affiliation:

1. Institute of Medical Mycology; Teikyo University; Tokyo Japan

2. Sato Pharmaceutical Co., Ltd; Tokyo Japan

Funder

Sato Pharmaceutical Co., Ltd, Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14607/fullpdf

Reference25 articles.

1. 2011 Epidemiological survey of dermatomycoses in Japan;Epidemiological Investigation Committee for Human Mycoses in the Japanese Society for Medical Mycology (Chairman and Reporter Yoshihiro Sei);Med Mycol J,2015

2. Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis;Yamaguchi;Med Mycol J,2016

3. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis;Gupta;J Eur Acad Dermatol Venereol,2005

4. In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses;Yamaguchi;Med Mycol J,2014

5. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp;Pfaller;Antimicrob Agents Chemother,2002

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploratory study on short‐term administration of oral fosravuconazole for tinea pedis;The Journal of Dermatology;2024-09-10

2. Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial;The Lancet Infectious Diseases;2024-08

3. Lessons learnt from conducting a randomised clinical trial in eumycetoma;The Lancet Infectious Diseases;2024-08

4. Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis;Expert Review of Anti-infective Therapy;2024-06-02

5. Effects of additional oral fosravuconazole l‐lysine ethanolate therapy following inadequate response to initial treatment for onychomycosis: A multicenter, randomized controlled trial;The Journal of Dermatology;2024-03-14